A nationwide voluntary recall has been issued for 22 lots of Argatroban Injection due to the presence of multi-material particulate contamination, posing potential life-threatening risks.
Vanda Pharmaceuticals has paused the clinical program for VQW-765 after a phase 3 trial evaluating the drug for social anxiety disorder failed to show significant distress reduction compared with ...
The expansion marks the first therapy approved for patients with BCG-unresponsive non-muscle-invasive bladder cancer presenting with papillary-only disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results